Prévisions

L'objectif de cours moyen des analystes est de 32,22 € (+55,28 %). La médiane est de 27,62 € (+33,11 %).

Actualités Accéder au fil d'actualités

Seaport Therapeutics reports quarterly loss of $0.28 per share

Seaport Therapeutics reported a loss per share of $0.28 for the quarter ended June 30, 2026, unchanged from the same quarter a year earlier. No further financial details were disclosed in the report. » Plus sur finanzen.net
Seaport Therapeutics reports quarterly loss of $0.25 per share

Seaport Therapeutics reported a loss per share of $0.25 for the quarter ended March 31, 2026, unchanged from the year-ago quarter. No further financial details were highlighted in the statement. » Plus sur finanzen.net
Seaport Therapeutics: GlyphAgo achieves therapeutic agomelatine levels without liver warning signals

Seaport Therapeutics published positive phase‑1 data on GlyphAgo (SPT‑320) in 174 healthy volunteers evaluating safety, tolerability and pharmacokinetics. Across all dose levels there were no serious or liver‑related adverse events and no clinically significant changes in liver parameters. GlyphAgo achieved therapeutic agomelatine levels, showed a 6.8‑fold increase in bioavailability versus unmodified agomelatine and a tenfold lower pharmacokinetic variability. Seaport plans a phase‑2a in H2 2026 for generalized anxiety disorder with sleep disturbance and a phase‑2b starting in H1 2027; topline results are expected in early and late 2028, respectively. » Plus sur de.investing.com

Au dernier trimestre, SEAPORT THERAP. DL-,0001 a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -54,85 M €